Head-to-head · free
Medtronic Plc vs NeoGenomics, Inc.
MDT vs NEO — return on capital, cash generation, margins and balance sheet side by side.
MDT
5 / 6
measures where MDT leads
NEO
1 / 6
measures where NEO leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | MDT · FY2026 | NEO · FY2025 |
|---|---|---|
| Revenue | $36.4B | — |
| Net income | $4.8B | (108.0M) |
| Revenue growth (yearly, multi-year) | 3.5% | — |
| Free cash flow | $5.4B | (21.8M) |
| Free cash flow margin | 14.9% | — |
| Net cash / (debt) | — | — |
| ROIC | 6.5% | — |
| Return on equity | 9.8% | -12.4% |
| Gross margin | 65.0% | 43.2% |
| Operating margin | 18.8% | -12.1% |
| Net debt / EBITDA | 2.75x | -3.79x |
Figures are as reported by each company; latest fiscal year shown.
Where Medtronic Plc's cash went (FY2026)
- Capital spending
- $1.9B
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where NeoGenomics, Inc.'s cash went (FY2025)
- Capital spending
- $27.0M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free